Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability.

ABSTRACT:

Objectives

The RV144 vaccine trial resulted in a decreased risk of HIV acquisition that was associated with a nonneutralizing antibody response. The objective of this study was to determine the impact of an additional boost to the RV144 vaccine regimen on antibody effector function and durability.

Design

RV306 was a randomized, double-blind late boosting of the RV144 prime-boost regimen in HIV-uninfected Thai adults (NCT01931358). This analysis included study participants who received the RV144 vaccine regimen and received no additional boost (group 1) or were boosted with ALVAC-HIV and AIDSVAX (group 2) or only AIDSVAX alone (group 3) 24 weeks after completing the RV144 series.

Methods

Plasma samples from RV306 study participants were used to measure antibody-depende

SUBMITTER: Shubin Z 

PROVIDER: S-EPMC10355803 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature